• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Veradermics, Incorporated Common Stock (NY:MANE)

122.28 +13.46 (+12.37%)
Official Closing Price Updated: 4:10 PM EDT, Oct 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,462,995
Open 115.34
Bid (Size) 121.35 (100)
Ask (Size) 125.00 (100)
Prev. Close 108.82
Today's Range 113.00 - 123.93
52wk Range 32.00 - 136.72
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Veradermics Phase III Hair Loss Trial Meets All Endpoints, Posts Strong Growth Results ↗
Today 13:02 EDT
Veradermics (NYSE:MANE) reported positive top-line results from Part A of Study 304, its second Phase III trial of VDPHL01, an extended-release oral minoxidil tablet being developed for men with mild... 
Via MarketBeat
News headline image
Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 3 ‘304’ Clinical Trial in Male Pattern Hair Loss
Today 7:00 EDT
From Veradermics, Incorporated
Via Business Wire

Performance

52-Week Range 10.6% below 52-week high
122.28
32.0052W Low 136.7252W High
1 Week 5.9% below 1-week high
106.511W Low 129.991W High

Veradermics, Incorporated Common Stock (MANE) traded between $32.00 and $136.72 over the past 52 weeks and last traded at $122.28, 10.6% below its 52-week high. Over the past week it ranged between $106.51 and $129.99.

Past 12 Months
-0.1%
+14.5%
+15.3%
+65.3%
+223.9%
+223.9%
1W -$0.12
1M +$15.53
3M +$16.24
6M +$48.31
YTD +$84.53
1Y +$84.53

MANE was +223.9% over the past year, +65.3% over six months, +223.9% year to date, -0.1% in the last week.

12 Months vs Market
MANE
+223.9%
DIA
+11.1%
SPY
+14.2%
QQQ
+17.5%
IWM
+9.3%

Over the past 12 months MANE returned +223.9% versus DIA (Dow) +11.1%, SPY (S&P 500) +14.2%, QQQ (Nasdaq 100) +17.5% and IWM (Russell 2000) +9.3%.

Volume & Liquidity 1.89× 3-mo avg
Today 1,462,995 3-mo avg 775.3K
1W
737.0K
1M
944.1K
3M
775.3K
6M
736.2K
YTD
656.6K
1Y
656.6K

MANE most recently traded 1,462,995 shares against a 3-month average daily volume of 775.3K.

More News

Read More
News headline image
Veradermics to Hold Conference Call to Discuss Topline Results from Phase 3 ‘304’ Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss
October 18, 2026
From Veradermics, Incorporated
Via Business Wire
News headline image
Veradermics to Present at Upcoming September Investor Conferences
September 03, 2026
From Veradermics, Incorporated
Via Business Wire
News headline image
Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
August 11, 2026
From Veradermics, Incorporated
Via Business Wire
News headline image
Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302’ in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy
July 17, 2026
From Veradermics, Incorporated
Via Business Wire
News headline image
Veradermics Hair Loss Pill Shows Strong Phase II Signal in Women ↗
July 15, 2026
Via MarketBeat
News headline image
Veradermics’ Oral VDPHL01 Delivers Positive Study ‘207’ Phase 2 Clinical Trial Results in Female Pattern Hair Loss Ahead of Upcoming Phase 2/3 Study ‘306’ Readout
July 15, 2026
From Veradermics, Incorporated
Via Business Wire
News headline image
Veradermics to Hold Conference Call to Discuss Study ‘207’ Phase 2 Clinical Trial Results of VDPHL01 in Females with Mild-to-Moderate Pattern Hair Loss
July 14, 2026
From Veradermics, Incorporated
Via Business Wire
News headline image
Veradermics to Present at Upcoming June Investor Conferences
May 28, 2026
From Veradermics, Incorporated
Via Business Wire
News headline image
Veradermics Announces Poster Presentation on Topline Results from Phase 2/3 ‘302’ Study of VDPHL01 at the 2026 World Congress for Hair Research
May 27, 2026
From Veradermics, Incorporated
Via Business Wire
News headline image
This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPO ↗
May 14, 2026
Via The Motley Fool
Topics Initial Public Offering
News headline image
Veradermics Announces Two Poster Presentations on VDPHL01 at the 2026 Music City SCALE Symposium
May 14, 2026
From Veradermics, Incorporated
Via Business Wire
News headline image
Veradermics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
May 12, 2026
From Veradermics, Incorporated
Via Business Wire
News headline image
Veradermics Announces Pricing of Upsized Public Offering and Private Placement
April 29, 2026
From Veradermics, Incorporated
Via Business Wire
News headline image
Veradermics Announces Launch of Public Offering
April 27, 2026
From Veradermics, Incorporated
Via Business Wire
These stocks are moving in today's session ↗
April 27, 2026
Via Chartmill
Top stock movements in today's session. ↗
April 27, 2026
Via Chartmill
These stocks are gapping in today's session ↗
April 27, 2026
Via Chartmill
Top movers in Monday's pre-market session ↗
April 27, 2026
Via Chartmill
News headline image
Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 2/3 ‘302’ Clinical Trial in Male Pattern Hair Loss
April 27, 2026
From Veradermics, Inc.
Via Business Wire
News headline image
Veradermics to Hold Conference Call to Discuss Topline Results from Phase 2/3 ‘302’ Study of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss
April 26, 2026
From Veradermics, Incorporated
Via Business Wire
News headline image
Veradermics Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Corporate and Clinical Updates
March 30, 2026
From Veradermics, Incorporated
Via Business Wire
News headline image
Veradermics Announces Presentations on VDPHL01 and Patient Experiences With Pattern Hair Loss at 2026 American Academy of Dermatology Annual Meeting
March 18, 2026
From Veradermics, Incorporated
Via Business Wire
News headline image
Veradermics to Participate in Upcoming March Investor Conferences
March 03, 2026
From Veradermics, Incorporated
Via Business Wire

Frequently Asked Questions

Is Veradermics, Incorporated Common Stock publicly traded?
Yes, Veradermics, Incorporated Common Stock is publicly traded.
What exchange does Veradermics, Incorporated Common Stock trade on?
Veradermics, Incorporated Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Veradermics, Incorporated Common Stock?
The ticker symbol for Veradermics, Incorporated Common Stock is MANE on the New York Stock Exchange
What is the current price of Veradermics, Incorporated Common Stock?
The current price of Veradermics, Incorporated Common Stock is 122.28
When was Veradermics, Incorporated Common Stock last traded?
The last trade of Veradermics, Incorporated Common Stock was at 10/19/26 04:10 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap